Twist Bioscience CORP Form 4 insider transactions
NASDAQ
Twist Bioscience's President and COO, Patrick John Finn, sold 2,232 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.
NASDAQ
Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,449 shares of common stock at $38.146 per share to satisfy tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 125 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Patrick John Finn, President and COO of Twist Bioscience Corp, sold 209 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Twist Bioscience CEO Emily M. Leproust sold 476 shares of common stock to cover tax withholding obligations related to vested restricted stock units.
NASDAQ
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation, sold 142 shares of common stock to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units.
NASDAQ
Twist Bioscience Corporation's CEO, Emily M. Leproust, reported a non-discretionary sale of 1,678 common shares to satisfy tax withholding obligations related to vested Restricted Stock Units.
NASDAQ
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp., executed a non-discretionary sale of 292 common stock shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Dennis Cho, SVP and Chief Legal Officer of Twist Bioscience, sold 230 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.
NASDAQ
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 94 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.
NASDAQ
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp., sold 257 shares of common stock for tax withholding purposes related to Restricted Stock Unit vesting.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 853 shares of common stock on June 6, 2025, at $31.75 per share to satisfy tax withholding obligations related to Restricted Stock Unit vesting.
NASDAQ
Twist Bioscience CEO Emily M. Leproust sold 2,170 shares of common stock on June 6, 2025, at $31.75 per share, solely to satisfy tax withholding obligations related to vested Restricted Stock Units.
NASDAQ
Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, sold 225 shares of common stock at $31.75 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Twist Bioscience Corp.'s Chief Accounting Officer, Robert F. Werner, sold 839 shares of common stock for $27.728 per share to satisfy tax withholding obligations related to Restricted Stock Unit vesting.
NASDAQ
Twist Bioscience Corporation's CEO, Emily M. Leproust, sold 2,802 shares of common stock at $29.747 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 531 shares of common stock to satisfy tax withholding obligations related to vested restricted stock units.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 632 shares of common stock at $29.747 per share to satisfy tax withholding obligations related to Restricted Stock Unit vesting.
NASDAQ
Form 4: Twist Bioscience President and COO Executes Non-Discretionary Stock Sale for Tax Obligations
Patrick John Finn, President and COO of Twist Bioscience Corp., sold 1,877 shares of common stock at $29.747 per share to cover tax withholding obligations related to Restricted Stock Units vesting, a non-discretionary transaction.
NASDAQ
Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 242 shares of common stock for $29.747 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Twist Bioscience Chief Financial Officer Adam Laponis sold 936 shares of common stock for tax withholding purposes related to restricted stock unit vesting.
NASDAQ
Patrick John Finn, President and COO of Twist Bioscience Corp, sold 20,000 shares of common stock at an average price of $32.313 on May 8, 2025.
NASDAQ
CEO Emily Leproust reported a gift of 3,000 shares to a charitable donor-advised fund and detailed her holdings of Twist Bioscience stock options.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience, sold 5,000 shares of common stock on May 7, 2025, at an average price of $32.718 per share.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience, sold 689 shares of common stock on May 5, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Patrick John Finn, President and COO of Twist Bioscience, sold 2,800 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, sold 162 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience, sold 1,101 shares of common stock on May 5, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
CEO of Twist Bioscience, Emily Leproust, sold 5,042 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Patrick John Finn, President and COO of Twist Bioscience Corp., sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.